Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

UPXI

Upexi Inc

Feb 13 • 04:00PM ET

0.7688

+0.0253 3.40 %

Communication Services • Internet Content & Information • USA • NASD

Peers: FUTU CNF JFIN AIOS OCFT JFU BTBT SOS UOKA STCN

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-5.24	Insider Own	14.59%	Shs Outstand	62.80M	Perf Week	-32.56%
Market Cap	53.31M	Forward P/E	-	EPS next Y	-0.28	Insider Trans	4.66%	Shs Float	59.22M	Perf Month	-68.75%
Enterprise Value	100.47M	PEG	-	EPS next Q	-0.10	Inst Own	31.02%	Short Float	20.35%	Perf Quarter	-77.25%
Income	-122.93M	P/S	2.15	EPS this Y	31.65%	Inst Trans	4.10%	Short Ratio	2.80	Perf Half Y	-90.27%
Sales	24.74M	P/B	0.99	EPS next Y	73.61%	ROA	-85.17%	Short Interest	12.05M	Perf YTD	-54.24%
Book/sh	0.78	P/C	0.32	EPS next 5Y	-	ROE	-468.50%	52W High	22.57 -96.59%	Perf Year	-80.78%
Cash/sh	2.40	P/FCF	-	EPS past 3/5Y	12.60% 25.24%	ROIC	-63.60%	52W Low	0.71 7.83%	Perf 3Y	-98.96%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-11.83% 16.36%	Gross Margin	78.37%	Volatility	13.69% 10.87%	Perf 5Y	-
Dividend TTM	-	EV/Sales	4.06	EPS Y/Y TTM	79.46%	Oper. Margin	-114.84%	ATR (14)	0.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.19	Sales Y/Y TTM	-	Profit Margin	-496.88%	RSI (14)	22.45	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.20	EPS Q/Q	-136.29%	SMA20	-50.36%	Beta	-0.32	Target Price	5.00
Payout	-	Debt/Eq	4.38	Sales Q/Q	101.02%	SMA50	-60.22%	Rel Volume	0.79	Prev Close	0.74
Employees	59	LT Debt/Eq	2.97	Earnings	Feb 10 AMC	SMA200	-86.09%	Avg Volume	4.30M	Price	0.77
IPO	Jun 24, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-3820.00% -56.40%	Trades		Volume	3,403,688	Change	3.40%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-04-25	Initiated	Alliance Global Partners	Buy	$15
Jun-16-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$16

Feb-12-26 08:03PM	Upexi Inc (UPXI) Q2 2026 Earnings Call Highlights: Revenue Soars Amid Digital Asset Challenges (GuruFocus.com) -8.91%
Feb-11-26 08:30AM	Upexi, Inc. Q2 2026 Earnings Call Summary (Moby) -16.30%
Feb-10-26 08:07PM	Upexi Q2 Earnings Call Highlights (MarketBeat) -7.13%
04:35PM	Upexi Reports Fiscal Second Quarter 2026 Financial Results (GlobeNewswire)
Feb-09-26 08:00AM	Upexi to Participate in A.G.P.'s Digital Asset Innovation Summit on February 22-25 (GlobeNewswire) -7.89%
08:33AM	Loading…
Feb-06-26 08:33AM	Upexi Announces Pricing of $7.4 Million Registered Direct Offering With a Single Institutional Investor (GlobeNewswire)
Jan-29-26 08:00AM	Upexi to Host Second Quarter 2026 Earnings Call on February 10th at 5:30 p.m. ET (GlobeNewswire) -6.63%
Jan-13-26 08:00AM	Upexi Announces Pricing of $36 Million Private Placement of Convertible Note Priced Above the Market (GlobeNewswire)
Jan-09-26 08:00AM	Upexi to Participate in Upcoming January Investor Conferences (GlobeNewswire)
Jan-07-26 08:00AM	Upexi Moves to High-Return Treasury Strategy (GlobeNewswire) -5.70%
Jan-06-26 07:40PM	Solana treasury firm cuts ties with analyst over default allegations (TheStreet)
Dec-30-25 08:00AM	Upexi to Ring the Nasdaq Closing Bell on Monday, January 5th, 2026 (GlobeNewswire)
Dec-24-25 03:14AM	Upexi Shares Slide After $1B Filing to Expand Solana Treasury (Cryptonews)
Dec-23-25 01:38PM	Bitcoin slips, crypto stocks suffer steep declines, as tax-loss selling drives action, analysts say (CoinDesk) -7.54%
11:30AM	Solana treasury-focused Upexi files for up to $1 billion capital raise (CoinDesk)
09:03AM	Loading…
09:03AM	Upexi Files Shelf Registration Statement on Form S-3 with the U.S. SEC (GlobeNewswire)
Dec-03-25 08:00AM	Upexi to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Dec-02-25 08:00AM	Upexi, Inc. Announces Closing of up to $23 Million Private Placement Common Stock and Warrants Offering (GlobeNewswire) +9.04%
Nov-26-25 08:00AM	Upexi, Inc. Announces Pricing of up to $23 Million Private Placement Offering of Common Stock and Warrants Priced above the At-the-Market Price under Nasdaq Rules (GlobeNewswire) -7.02%
Nov-14-25 07:49AM	Upexi CSO Explains Why the Next Wave of Corporate Finance Is Moving On-Chain (BeInCrypto) -7.14%
Nov-13-25 06:00PM	Crypto Treasuries Turn Defensive as Solana Upexis Buyback Adds to Growing DAT Trend (Cryptonews)
11:31AM	Solana-Focused Upexi Approves $50M Share Buyback as Digital Asset Treasuries Turn to Repurchases (CoinDesk)
08:30AM	Upexi Announces $50 Million Share Repurchase Program (GlobeNewswire)
Nov-12-25 08:02PM	Upexi CEO says Solana staking fueled 183% profit surge, calls it 'the future of financial rails' (TheStreet) +5.30%
12:04AM	Upexi Inc (UPXI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Digital ... (GuruFocus.com)
Nov-11-25 05:25PM	Upexi Reports Record Digital Asset Revenue for Fiscal First Quarter 2026 (GlobeNewswire)
Nov-06-25 08:00AM	Upexi to Host First Quarter 2026 Earnings Call on November 11th at 5:30 p.m. ET (GlobeNewswire) -9.93%
Nov-05-25 11:29AM	TradFi Solana Price Prediction is BULLISH? Solana Treasuries Keep Stacking SOL (99bitcoins)
Nov-04-25 08:00AM	Key Metrics Demonstrate Upexi's Proven Shareholder Value Creation (GlobeNewswire) -8.85%
Oct-31-25 08:00AM	Upexi to Participate in Upcoming November Investor Conferences (GlobeNewswire)
06:45PM	Loading…
Oct-23-25 06:45PM	Trading legend Jon Najarian joins Solana DAT Upexi as advisor (TheStreet)
08:00AM	Upexi Welcomes Jon Najarian to the Upexi Advisory Committee (GlobeNewswire)
Oct-06-25 08:00AM	Upexi to Participate in Upcoming October Investor Conferences (GlobeNewswire)
Sep-30-25 08:00AM	Upexi Welcomes SOL Big Brain to the Upexi Advisory Committee (GlobeNewswire)
Sep-26-25 06:12AM	Solana Treasury Gains Cushion Upexi's Business Losses (CCN)
Sep-24-25 05:55PM	Upexi Reports Financial Results for Fiscal Year Ended June 30, 2025 and Provides Shareholders with Solana Treasury Update Since June 30, 2025 (GlobeNewswire) -14.29%
Sep-15-25 07:17PM	Experts Call For $500 SOL USD: Corporate Treasuries Bid as Solana Signals Breakout (99bitcoins) -6.29% -8.06%
Sep-12-25 09:15AM	Upexi Builds $447 Million Solana Treasury And Bets On AI-Driven Alpha Exchange Launch (Benzinga) +18.93%
Sep-11-25 05:07PM	Solana Treasury Firms Boost Holdings to 6.5M SOL as Upexi Posts 126% Surge (Cryptonews)
08:00AM	Upexi Adjusted SOL per Share Increases 129% Since Treasury Launch (GlobeNewswire)
Sep-08-25 08:52AM	Forward Industries (FORD) to become largest Solana treasury holder through $1.6B deal, stock jumps 101% (CryptoSlate) -6.29%
06:30AM	Forward Industries Raises $1.65B to Launch Solana Treasury, Shares Surge 128% Pre-Market (CoinDesk)
Sep-03-25 08:00AM	Upexi to Participate in Upcoming September Conferences (GlobeNewswire)
Aug-28-25 08:00AM	Upexi, Inc. Announces Strategic Investment in Alpha Exchange (GlobeNewswire)
Aug-27-25 02:34PM	Institutions Hold $1.72 Billion In Solana, Strategic Reserve Data Reveals (Benzinga)
Aug-26-25 12:43PM	Bitcoin Shatters $124,000 Record as $15 Billion Digital Treasury Wave Transforms Corporate America (PR Newswire) +12.57%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-19-25 05:07PM	Strategy Tumbles to 4-Month Low as Crypto Stocks, Digital Asset Treasuries Sink (CoinDesk) -8.96% +11.90%
Aug-14-25 12:21PM	Crypto Treasury Revolution: How $47B Corporate Shift Creates New Investment Opportunities (PR Newswire)
Aug-13-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +17.57%
Aug-12-25 02:08PM	Former Amazon aggregator turns to Solana, records $70K in daily rewards (TheStreet) +18.51%
08:00AM	Upexi Establishes Advisory Committee and Welcomes Arthur Hayes as First Member (GlobeNewswire)
Aug-11-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) -6.95%
Aug-05-25 08:00AM	Upexi Surpasses 2 Million SOL in its Treasury (GlobeNewswire)
08:00AM	Solana Treasury Company Upexi Surpasses 2M in SOL Holdings (CoinDesk)
Jul-30-25 08:00AM	Upexi to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference on August 12th-14th (GlobeNewswire) -10.04%
Jul-28-25 01:16PM	Nasdaq-Listed Upexi Secures $500M Equity Line to Expand Solana Treasury Holdings (CoinDesk)
08:00AM	Upexi, Inc. Announces $500 Million Equity Line Agreement with A.G.P. to Accelerate the Growth of its Solana Treasury Strategy (GlobeNewswire)
Jul-25-25 09:29AM	Why Are Public Companies Amassing ETH, XRP, SOL, BNB Instead Of Just Bitcoin? (Benzinga)
Jul-23-25 08:00AM	Upexi Purchases 83,000 SOL, Grows Treasury to 1.9 Million SOL Worth $381 Million (GlobeNewswire) -12.99%
06:14AM	Solana's SOL Could Hit $500 in This Bull Run, Says Analyst, as Upexi Boosts Holdings to 1.8M SOL (CoinDesk)
Jul-21-25 08:00AM	Upexi Grows Treasury to 1.819 Million SOL Worth $331 Million with a $58 Million Unrealized Gain in Under Three Months (GlobeNewswire) +8.96%
Jul-17-25 08:00AM	Upexi Announces Closing of Approximately $150 Million Private Placement of Convertible Notes as Part of Previously Announced $200 Million Concurrent Offering (GlobeNewswire)
Jul-15-25 12:16PM	Solana News: $500M Pump.fun ICO Sells Out as BTC Hits New ATH (CoinMarketCap) -12.75%
08:36AM	Upexi Announces Closing of $50 Million Private Placement Equity Offering (GlobeNewswire)
Jul-11-25 12:04PM	SOL: Nasdaq-Listed Firm Secures $200M in Financing, with Over $150M Tied to Solana Treasury Strategy (CoinDesk) +7.80%
08:30AM	Upexi, Inc. Announces Pricing of $200 Million Concurrent Private Placement of Common Stock and Convertible Notes both Priced above the At-the-Market Price under Nasdaq Rules (GlobeNewswire)
Jul-08-25 08:00AM	Upexi, Inc. June 2025 Monthly Update (GlobeNewswire) +26.69%
Jul-01-25 07:00AM	Michael Saylors Strategy to Join Wall Street Elite With $14 Billion Windfall (Bloomberg)
Jun-26-25 11:09AM	Solana-Focused Upexi to Tokenize Shares; Added 56K SOL to Holdings (CoinDesk) -5.11%
08:00AM	Upexi Announces Intent to List SEC-Registered Shares On-Chain via Superstate's Opening Bell (GlobeNewswire)
Jun-18-25 10:05AM	ICR Presents Public Market Crypto Balance Sheet Strategies June 20, 11AM ET (IPO-Edge.com) +12.51%
Jun-17-25 04:05PM	Nakamoto Holdings to Participate in ICR Conference Spotlight Series (Business Wire)
10:22AM	SOL Drops Below $150 After Sell-Off Despite Growing Institutional Adoption Narrative (CoinDesk)
09:46AM	IPO Edges Jannarone: Circle and The Rise of Publicly-Traded Crypto Treasury Companies Schwab TV (IPO-Edge.com)
09:00AM	Upexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20th (GlobeNewswire)
Jun-16-25 02:45PM	Solana Treasury Strategy Better Than ETH, Firms Buying SOL Should Trade at Premium: Cantor (CoinDesk)
Jun-12-25 09:00AM	Upexi CEO and CSO to Host Fireside Chat on Thursday, June 26th at 11:00 a.m. ET (GlobeNewswire)
Jun-10-25 10:33AM	HODL On Tight: The Meteoric Rise of Crypto Treasury Companies Industry Overview Report (Exec Edge)
Jun-09-25 09:00AM	Upexi Joins Webull Corporate Connect Service Platform (GlobeNewswire) +6.96%
Jun-05-25 09:00AM	Upexi Approved for Options Trading on Nasdaq (GlobeNewswire) +6.14%
May-30-25 08:00AM	Upexi to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25 (GlobeNewswire) +7.91%
May-29-25 08:00AM	Upexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused Strategy (GlobeNewswire)
May-28-25 09:20AM	Upexi releases presentation detailing Solana treasury strategy (TipRanks)
09:08AM	Upexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 million (GlobeNewswire)
May-27-25 09:00AM	Upexi Releases Investor Presentation Detailing Solana Treasury Strategy (ACCESSWIRE) -7.02%
May-22-25 08:00AM	Upexi Appoints Brian Rudick, CFA as Chief Strategy Officer (ACCESSWIRE) +6.81%
May-16-25 09:00AM	Upexi Reports First Quarter 2025 Financial Results and Provides Update on Solana Treasury Strategy (ACCESSWIRE) +6.37%
May-13-25 09:00AM	BitGo and Upexi Announce Strategic Partnership to Secure Digital Asset Treasury Holdings (Business Wire) -5.92%
May-12-25 08:50AM	Eric Trump-backed American Bitcoin to go public through all-stock merger (Reuters) +7.37%
08:00AM	Upexi Buys Discounted Locked SOL, Surpasses $100 Million of SOL and Becomes the Largest Publicly-Traded Solana Treasury Company (ACCESSWIRE)
May-06-25 08:00AM	Upexi Increases Solana Treasury to 201,500 Solana Tokens for $30 Million and Begins to Generate Staking Revenue (ACCESSWIRE)
Apr-30-25 04:25PM	Crypto Stocks Emerge Unscathed From Aprils Market Turmoil (Bloomberg) -14.06% +9.69%
Apr-29-25 12:15PM	CORRECTION FROM SOURCE: Upexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana Strategy (ACCESSWIRE)
08:00AM	Upexi Purchases 45,733 Solana Tokens as it Begins Deploying $100 Million Treasury in Solana Strategy (ACCESSWIRE)
Apr-24-25 04:10PM	Upexi Announces Closing of $100 Million Private Placement (ACCESSWIRE) +22.80% +14.72%
Apr-22-25 09:51AM	Why Upexi, Inc. (UPXI) Soared on Monday (Insider Monkey) -9.00%
Apr-21-25 11:22AM	Solana Pushes Higher As Staking Milestone And Institutional Bets Fuel Rally (Benzinga) +330.94%
11:09AM	GSR Anchors $100M Investment in Upexi to Purchase SOL, Stock Rockets 700% (CoinDesk)
08:00AM	Upexi Announces Pricing of $100 Million Private Placement Priced Above Last Market Closing Price under Nasdaq Rules (ACCESSWIRE)

Upexi, Inc. engages in the development, manufacturing, and distribution of consumer products through direct-to-consumer network, wholesale partnerships, and major third-party platforms like Amazon. Its brands include LuckyTail, Prax, Cure Mushrooms, Moonwlkr, and Gumi Labs. The company was founded on September 5, 2018 and is headquartered in Tampa, FL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARSHALL ALLAN	Chief Executive Officer	Dec 23 '25	Buy	1.80	50,000	90,000	4,046,261	Dec 23 07:53 PM
MARSHALL ALLAN	Chief Executive Officer	Dec 15 '25	Buy	2.07	100,000	207,000	3,946,261	Dec 17 06:43 PM
MARSHALL ALLAN	Chief Executive Officer	Dec 16 '25	Buy	2.07	50,000	103,500	3,996,261	Dec 17 06:43 PM
Salkind Gene	Director	Nov 20 '25	Buy	2.55	50,000	127,500	218,750	Nov 21 06:32 AM
Salkind Gene	Director	Nov 17 '25	Buy	2.81	100,000	281,000	168,750	Nov 18 09:40 PM
Salkind Gene	Director	Nov 17 '25	Buy	2.65	100,000	265,000	569,470	Nov 18 09:40 PM
Salkind Gene	Director	Jul 11 '25	Buy	4.94	20,243	100,000	385,370	Jul 30 04:47 PM
Dugan Lawrence	Director	Jul 16 '25	Buy	5.69	11,000	62,600	112,389	Jul 24 04:05 PM
Dugan Lawrence	Director	Jul 22 '25	Buy	7.50	4,000	30,000	116,389	Jul 24 04:05 PM
Dugan Lawrence	Director	Jul 15 '25	Buy	5.17	1,000	5,170	1,389	Jul 24 04:05 PM
MARSHALL ALLAN	Chief Executive Officer	Jul 11 '25	Buy	4.94	161,943	799,998	1,046,261	Jul 24 04:03 PM
MARSHALL ALLAN	Chief Executive Officer	Apr 17 '25	Buy	2.28	657,895	1,500,001	809,318	Apr 25 04:01 PM
Norstrud Andrew James	Chief Financial Officer	Apr 17 '25	Buy	2.28	43,860	100,001	59,138	Apr 25 04:01 PM
Salkind Gene	Director	Apr 17 '25	Buy	2.28	241,229	550,002	365,127	Apr 25 04:01 PM

Open in Screener

COEP

Coeptis Therapeutics Holdings Inc

Feb 13 • 04:00PM ET

12.11

+0.29 2.45 %

Healthcare • Biotechnology • USA • NASD

COEP Coeptis Therapeutics Holdings Inc daily Stock Chart

Peers: GILD REGN PFE MRNA BNTX JNJ VRTX AZN-D AMGN LLY

| Held by: VTI VXF

Index	-	P/E	-	EPS (ttm)	-3.95	Insider Own	11.31%	Shs Outstand	5.16M	Perf Week	7.45%
Market Cap	69.78M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	5.11M	Perf Month	-14.30%
Enterprise Value	65.28M	PEG	-	EPS next Q	-	Inst Own	7.42%	Short Float	8.88%	Perf Quarter	-16.54%
Income	-12.34M	P/S	139.56	EPS this Y	-	Inst Trans	12.16%	Short Ratio	5.69	Perf Half Y	5.49%
Sales	0.50M	P/B	5.01	EPS next Y	-	ROA	-90.30%	Short Interest	0.45M	Perf YTD	-15.02%
Book/sh	2.42	P/C	13.09	EPS next 5Y	-	ROE	-127.31%	52W High	21.41 -43.44%	Perf Year	-1.82%
Cash/sh	0.92	P/FCF	-	EPS past 3/5Y	38.79% -322.46%	ROIC	-97.84%	52W Low	6.26 93.45%	Perf 3Y	-62.16%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-592.22%	Volatility	8.26% 9.87%	Perf 5Y	-94.06%
Dividend TTM	-	EV/Sales	130.56	EPS Y/Y TTM	37.81%	Oper. Margin	-2638.23%	ATR (14)	1.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.21	Sales Y/Y TTM	-	Profit Margin	-2463.79%	RSI (14)	42.20	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.21	EPS Q/Q	37.18%	SMA20	-6.28%	Beta	-0.47	Target Price	80.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	-	SMA50	-14.22%	Rel Volume	0.44	Prev Close	11.82
Employees	7	LT Debt/Eq	0.01	Earnings	-	SMA200	-4.83%	Avg Volume	79.80K	Price	12.11
IPO	Dec 17, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	35,279	Change	2.45%

Feb-05-26 04:00PM	Coeptis Receives Shareholder Approval Towards Z Squared Merger (GlobeNewswire) -19.68% +6.22%
Jan-30-26 11:28AM	CSG Systems International Extraordinary General Meeting: Shareholders Back Key Proposals, Merger Actions (MarketBeat)
Jan-06-26 08:19AM	Coeptis Therapeutics S-4 Declared Effective by SEC, Proxy Mailing Begins in Anticipation of the Merger Transaction with Z Squared (GlobeNewswire)
Sep-23-25 08:00AM	Vanderbilt Report: Coeptis Shows How Biotech Can Fund Itself While Innovating (GlobeNewswire) +13.41%
Jul-22-25 08:36AM	Coeptis (COEP) Extinguishes Convertible Note with YA II PN, Ltd (GlobeNewswire)
08:34AM	Loading…
Jun-26-25 08:34AM	Coeptis (COEP) Announces Filing of Registration Statement on Form S-4 with SEC in Connection with Proposed Transaction with Z Squared (GlobeNewswire)
May-28-25 08:28AM	Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology (GlobeNewswire)
May-12-25 08:20AM	NUBURU Files $100M SEC Registration Statement to Enhance Capital Flexibility for Completion of Defense Acquisition and Blue Laser Technology Revitalization Targeting a $500B Defense Market (Business Wire)
Apr-25-25 08:33AM	Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement (GlobeNewswire) -38.25%
Apr-17-25 08:38AM	COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology (GlobeNewswire) +7.82%
Apr-15-25 08:33AM	NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives (Business Wire)
Mar-11-25 08:34AM	Coeptis Therapeutics Secures Worldwide Development and Commercialization Rights to Next-Generation GEAR Cell Therapy Platform Strengthening its High-Impact Precision Immuno-Oncology Pipeline (GlobeNewswire)
Mar-07-25 08:37AM	COEPTIS' NexGenAI Affiliates Partners with NUBURU Network to Drive Innovation in AI and Robotics as Part of its Transformation Plan (GlobeNewswire)
Mar-06-25 08:00AM	NUBURU Partners With COEPTIS NexGenAI Affiliates Network to Drive Innovation in AI and Robotics as Part of Its Transformation Plan (Business Wire) -5.09%
Feb-20-25 09:00AM	COEPTIS' NexGenAI Partners with Arketyp Valu to Revolutionize Digital Engagement on the Verus Network (GlobeNewswire) -16.44%
07:27AM	Loading…
07:27AM	COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-19-25 04:00PM	COEPTIS NexGenAI Affiliates Network & MarketLeverage Announce Strategic Partnership to Revolutionize AI-Powered Affiliate Marketing (GlobeNewswire)
Feb-13-25 08:39AM	COEPTIS Announces the Launch of COEP Venture Group to Invest in AI, RPA, and AI Agent Startups (GlobeNewswire)
Feb-06-25 08:08AM	COEPTIS Completes $10 Million Series A Preferred Financing Round, Reinforcing Commitment to Technological Innovation and AI Integration (PR Newswire)
Jan-30-25 08:27AM	Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation (PR Newswire)
Jan-23-25 08:09AM	Coeptis Therapeutics Leverages Artificial Intelligence and Blockchain for Next-Generation Innovation (PR Newswire) -9.81%
Jan-22-25 08:00AM	Coeptis Therapeutics Regains Compliance with Nasdaq Listing Rule 5550(a)(2) (PR Newswire) +13.56%
Jan-07-25 08:00AM	Coeptis Therapeutics Announces First Customer Adoptions of its NexGenAI Marketing Platform (PR Newswire)
Dec-27-24 08:15AM	Coeptis Therapeutics Announces Reverse Stock Split (PR Newswire) -13.65%
Dec-26-24 08:15AM	Coeptis Therapeutics Makes Bold Strides in Innovation with the Acquisition of NexGenAI Affiliates Network Platform and Launch of Coeptis Technologies (PR Newswire) +48.59%
Dec-12-24 08:00AM	Coeptis Therapeutics Unveils New Technology Division: Coeptis Technologies (PR Newswire)
Dec-03-24 08:15AM	Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries (PR Newswire) +17.51%
Nov-07-24 08:07AM	Coeptis Therapeutics Announces Phase 1 Data on DVX201 for COVID-19 Treatment Has Been Accepted for Publication in Molecular Therapy Methods and Clinical Development (PR Newswire)
Oct-24-24 08:07AM	Coeptis Therapeutics Expands License Agreement with Deverra to Include Pandemic Preparedness, and Emergency Use (PR Newswire) -6.64%
Oct-15-24 08:07AM	Coeptis Therapeutics' Chief Scientific and Medical Officer to Present at Upcoming Fall Conferences, Highlighting Progress in Universal Cell Therapy (PR Newswire)
07:07AM	Loading…
Sep-19-24 07:07AM	Coeptis Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (PR Newswire) +5.47%
Sep-05-24 08:07AM	Coeptis Therapeutics Chief Executive Officer, Dave Mehalick, Updates and Outlines Strategic Vision in Letter to Shareholders (PR Newswire) -5.66%
Aug-16-24 08:52PM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q2 2024 (InvestorPlace) +5.15%
Jun-20-24 08:47AM	Coeptis Therapeutics Closes on $4.3 Million of Series A Preferred Offering (PR Newswire) -8.81%
May-30-24 08:47AM	Coeptis Therapeutics' Dr. Colleen Delaney to Present at Allogeneic Cell Therapies Summit 6th Annual Meeting (PR Newswire)
May-13-24 09:53AM	COEP Stock Earnings: Coeptis Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.07%
May-08-24 08:47AM	Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024 (PR Newswire)
May-02-24 08:47AM	Coeptis Therapeutics Announces Poster Data Presentation at American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting (PR Newswire) +8.77%
Apr-02-24 08:47AM	Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award (PR Newswire) +6.68%
Feb-26-24 09:00AM	Coeptis Therapeutics Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK (PR Newswire) +9.89%
Feb-07-24 07:30AM	Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-in-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections (PR Newswire)
Jan-04-24 07:30AM	Coeptis Therapeutics President and CEO Issues Letter to Shareholders Highlighting 2023 Accomplishments and Outlook for 2024 (PR Newswire) -10.71%
Dec-06-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 2 on December 7th Register Now (GlobeNewswire) -7.02%
Dec-05-23 07:00AM	Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now (GlobeNewswire) -5.00%
Dec-04-23 07:30AM	Coeptis Therapeutics to Present at the Emerging Growth Conference (PR Newswire)
Oct-31-23 09:01AM	Coeptis Therapeutics Announces Research Demonstrating the Potential of SNAP-CAR T-cells to Reduce Tumor Burden and Growth in HER2 and CD20 Expressing Cancers Will be Presented at SITC 2023 (PR Newswire) -9.74%
07:00AM	Presenting on the Emerging Growth Conference 64 Day 1 on November 1 Register Now (GlobeNewswire)
Oct-24-23 08:30AM	Coeptis Therapeutics Announces $2 Million Private Placement (PR Newswire)
Oct-11-23 07:30AM	Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology (PR Newswire)
Oct-09-23 09:15AM	Coeptis Therapeutics to Participate in Panel at the BioFlorida Conference Discussing Emerging Cell and Gene Therapies (PR Newswire)
Oct-04-23 07:30AM	Coeptis Therapeutics Announces Research Involving SNAP-CAR Accepted for Presentation at the Society for Immunotherapy of Cancer's 38th Annual Meeting (PR Newswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Sep-27-23 07:30AM	Coeptis Therapeutics to Present at the 2023 Cell & Gene Meeting on the Mesa (PR Newswire) +10.31%
Sep-14-23 07:30AM	Coeptis Therapeutics Provides Safety and Dosing Update from Phase 1 Trials Investigating DVX201 in Relapsed/Refractory AML or High Risk MDS and Hospitalized COVID-19 Infection (PR Newswire)
Sep-11-23 07:30AM	Coeptis Therapeutics Announces Deverra Therapeutics Has Received Two Life Science Start-Up and Development Awards and Associated Grant from Washington's Cancer Research Endowment (PR Newswire) -5.29%
Aug-30-23 01:00PM	Coeptis Therapeutics Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer (PR Newswire)
Aug-17-23 07:30AM	Coeptis Therapeutics Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics (PR Newswire)
Aug-01-23 08:00AM	Coeptis Therapeutics Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic (PR Newswire)
Jun-16-23 04:00PM	Coeptis Therapeutics Holdings, Inc. Announces Closing of $3.5 Million Underwritten Offering (PR Newswire) -5.59%
Jun-14-23 09:28AM	Coeptis Therapeutics Holdings, Inc. Announces Pricing of $3.5 Million Underwritten Offering (PR Newswire) +6.06%
Jun-09-23 07:00AM	Coeptis Therapeutics Receives Approval to Transfer to The Nasdaq Capital Market (PR Newswire)
May-17-23 08:30AM	Coeptis Therapeutics Appoints Brian Cogley as Chief Financial Officer (PR Newswire)
May-10-23 03:00PM	Coeptis Therapeutics' SNAP-CAR Technology Platform for Programmable Antigen Targeting Featured in Peer-Reviewed Article in Nature Communications (PR Newswire)
Apr-18-23 07:30AM	Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Trials from Deverra Therapeutics (PR Newswire) +9.16%
Mar-29-23 09:45AM	Coeptis Therapeutics Secures Exclusive Rights to Negotiate to Acquire Transformational Cell Therapy Platform to Enable Potent Combinatorial Immuno-Oncology Treatment Strategies (PR Newswire)
Mar-21-23 07:00AM	Coeptis Therapeutics' SNAP-CAR Technology Platform Highlighted in Peer-Reviewed Article in Translational Medicine (PR Newswire)
Feb-07-23 08:00AM	Coeptis Therapeutics and ShareIntel Enter Shareholder Service Agreement, Targeting Illegal Short Selling (PR Newswire)
Jan-31-23 07:30AM	Coeptis Therapeutics Enters into Sponsored Research Agreement with the University of Pittsburgh to Advance SNAP-CAR Development Program (PR Newswire) +12.73%
Nov-22-22 07:00AM	Coeptis Therapeutics Engages IQVIA to Support SNAP-CAR Development Program (PR Newswire) -6.17%
Nov-15-22 07:00AM	Coeptis Therapeutics Holdings to Ring the Nasdaq Stock Market Opening Bell (PR Newswire)
Nov-08-22 07:00AM	Coeptis Therapeutics' Scientific Advisory Board Members Featured on "Biology of Natural Killer (NK) Cells" Podcast (PR Newswire) -17.13%
Nov-02-22 07:00AM	Coeptis Therapeutics Holdings Expands Board of Directors with New Appointments (PR Newswire) -8.81%
Sep-21-22 07:00AM	Coeptis Therapeutics Enters Exclusive License Agreement with University of Pittsburgh for Rights to SNAP-CAR, a "Multi-Antigen" CAR T Technology (PR Newswire)
May-17-22 07:00AM	Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors (PR Newswire)
Apr-19-22 07:00AM	Coeptis Therapeutics, Inc. and Bull Horn Holdings Corp. Announce Merger Agreement (PR Newswire)
Apr-13-22 04:05PM	Statera Biopharma and Coeptis Therapeutics Announce Strategic Agreement for Rights to Entolimod (GlobeNewswire)
07:00AM	Coeptis Therapeutics Announces Intent to Acquire TLR5 Agonist Platform, Including Clinical-Stage Asset Entolimod, from Statera Biopharma (PR Newswire)
Jan-20-22 08:00AM	Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product Development (PR Newswire)

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cogley Brian	Chief Financial Officer	Feb 11 '26	Option Exercise	10.56	10,000	105,600	22,500	Feb 13 05:00 PM
Deschamps Philippe	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	8,950	Feb 13 05:00 PM
Calise Chris	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	368,741	Feb 13 05:00 PM
Mehalick David	CEO and President	Feb 11 '26	Option Exercise	7.05	148,875	1,049,569	330,192	Feb 13 05:00 PM
Cochran Christopher P.	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	8,950	Feb 13 05:00 PM
Yerace Daniel Alexander	VP Operations	Feb 11 '26	Option Exercise	10.41	10,000	104,100	70,531	Feb 13 05:00 PM
Salkind Gene	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	13,161	Feb 13 05:00 PM
DeSilva Tara	Director	Feb 11 '26	Option Exercise	10.56	5,700	60,192	8,950	Feb 13 05:00 PM
Sheehy Christine Elise	VP Compliance and Secy	Feb 11 '26	Option Exercise	10.56	1,000	10,560	64,031	Feb 13 05:00 PM
Yerace Daniel Alexander	Director	Dec 15 '25	Proposed Sale	15.02	5,000	75,100		Dec 15 11:26 AM
Yerace Daniel Alexander	Director	Sep 02 '25	Proposed Sale	12.96	5,000	64,800		Sep 02 10:04 AM

UPXI

Upexi Inc

COEP

Coeptis Therapeutics Holdings Inc

Upgrade your FINVIZ experience